The estimated Net Worth of Minang Turakhia is at least $2.39 Million dollars as of 2 July 2024. Minang Turakhia owns over 1,404 units of iRhythm Technologies Inc stock worth over $2,039,492 and over the last 2 years Minang sold IRTC stock worth over $355,376.
Minang has made over 3 trades of the iRhythm Technologies Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Minang sold 1,404 units of IRTC stock worth $148,333 on 2 July 2024.
The largest trade Minang's ever made was selling 1,404 units of iRhythm Technologies Inc stock on 2 July 2024 worth over $148,333. On average, Minang trades about 556 units every 61 days since 2022. As of 2 July 2024 Minang still owns at least 27,255 units of iRhythm Technologies Inc stock.
You can see the complete history of Minang Turakhia stock trades at the bottom of the page.
Minang's mailing address filed with the SEC is C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO, CA, 94103.
Over the last 8 years, insiders at iRhythm Technologies Inc have traded over $124,847,276 worth of iRhythm Technologies Inc stock and bought 150,000 units worth $2,550,000 . The most active insiders traders include Holdings A/S Novo, Vijay K Lathi, and Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,872,546. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth $96,506.
irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
iRhythm Technologies Inc executives and other stock owners filed with the SEC include: